Respiratory care pharmacology:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
St. Louis [u.a.]
Mosby
1998
|
| Ausgabe: | 5. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XVII, 408 S. Ill., graph. Darst. |
| ISBN: | 081512337X |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV011994191 | ||
| 003 | DE-604 | ||
| 005 | 19980909 | ||
| 007 | t | ||
| 008 | 980609s1998 ad|| |||| 00||| eng d | ||
| 020 | |a 081512337X |9 0-8151-2337-X | ||
| 035 | |a (OCoLC)37213998 | ||
| 035 | |a (DE-599)BVBBV011994191 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 | ||
| 050 | 0 | |a RM388 | |
| 082 | 0 | |a 616.2/00461 |2 21 | |
| 084 | |a XI 4200 |0 (DE-625)153004:12905 |2 rvk | ||
| 100 | 1 | |a Rau, Joseph L. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Respiratory care pharmacology |c Joseph L. Rau |
| 250 | |a 5. ed. | ||
| 264 | 1 | |a St. Louis [u.a.] |b Mosby |c 1998 | |
| 300 | |a XVII, 408 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Bronchodilator Agents |x administration & dosage | |
| 650 | 4 | |a Bronchodilator Agents |x pharmacology | |
| 650 | 4 | |a Respiratory Therapy | |
| 650 | 4 | |a Respiratory agents | |
| 650 | 4 | |a Respiratory therapy | |
| 650 | 0 | 7 | |a Atemwege |0 (DE-588)4068903-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Atemwege |0 (DE-588)4068903-7 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008117173&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-008117173 | ||
Datensatz im Suchindex
| _version_ | 1804126589855727616 |
|---|---|
| adam_text | Contents
UNIT ONE
BASIC CONCEPTS AND PRINCIPLES
IN PHARMACOLOGY
1 Introduction to Respiratory Care
Pharmacology, 3
Introduction, 3
Pharmacology and the Study of Drugs, 3
Naming Drugs, 4
Sources of Drug Information, 5
Sources of Drugs, 5
Process of Drug Approval in the United States, 5
Chemical identification, 5
Animal studies, 6
Investigational new drug (IND) approval, 6
New drug application (NDA), 6
FDA new drug classification system, 7
Orphan drugs, 7
The Prescription, 7
Over the counter (OTC) drugs, 9
Generic substitution in prescriptions, 9
Respiratory Care Pharmacology—An Overview, 9
Aerosolized agents given by inhalation, 9
Related drug groups in respiratory care, 9
2 Principles of Drug Action, 12
Introduction, 12
The Pharmaceutical Phase, 12
Drug dosage forms, 12
Routes of administration, 13
The Pharmacokinetic Phase, 14
Absorption, 14
Distribution, 16
Metabolism, 17
Elimination, 19
Pharmacokinetics of inhaled aerosols, 21
The Pharmacodynamic Phase, 25
Structure activity relation, 25
Nature and type of drug receptors, 25
Dose response relations, 29
3 Administration of Aerosolized Agents, 34
Introduction, 34
Physical Principles of Inhaled Aerosol Drugs, 34
Aerosol particle size distributions, 35
Relation of particle size to drug volume, 35
Measurement of particle size distributions, 36
Particle size and lung deposition, 37
Mechanisms of deposition, 38
Effect of temperature and humidity, 39
Pattern of inhalation, 39
Aerosol Devices for Drug Delivery, 39
Nebulizers, 40
Metered dose inhalers (MDIs), 43
MDI reservoir devices, 48
Dry powder inhalers (DPIs), 50
Clinical Application of Aerosol Delivery Devices, 53
Criteria for choosing an aerosol delivery device, 53
Efficiency and loss patterns of aerosol delivery
devices, 53
Equivalent doses among device types, 55
Patient device interface, 55
Status of the lung, 59
4 Calculating Drug Doses, 63
Introduction, 63
Systems of Measure, 63
The metric system, 63
The SI system, 64
Drops as units of volume, 64
Household units of measure, 65
Calculating Doses from Prepared Strength Liquids,
Tablets, and Capsules, 65
Calculating with proportions, 65
Drug amounts in units, 66
Calculations with a dosage schedule, 66
Additional examples of calculations with prepared
strength drugs, 66
Calculating Doses from Percentage Strength
Solutions, 67
Types of percentage preparations, 67
Solutions by ratio, 67
Solving percentage strength solution problems, 68
Note on mixing solutions, 68
Percentage strengths in milligrams per
milliliter, 69
Diluents and drug doses, 69
Additional examples of calculations with
solutions, 69
Calculating Intravenous (IV) Infusion Rates, 70
Total solution over time, 71
Amount of drug per unit of time, 71
Additional examples of IV dose calculations, 71
xi
xii Contents
5 The Central and Peripheral Nervous System, 76
Introduction, 76
The Nervous System, 76
Anatomic description of the autonomic
branches, 77
Contrasts between parasympathetic and
sympathetic regulation, 78
Neurotransmitters, 78
Efferent and afferent nerve fibers, 79
Terminology of drugs affecting the nervous
system, 79
Parasympathetic Branch, 80
Cholinergic neurotransmitter function, 80
Muscarinic and nicotinic receptors and effects, 81
Subtypes of muscarinic receptors, 82
Parasympathomimetic Agents, 82
Direct acting, 82
Indirect acting, 83
Parasympatholytic agents, 84
Atropine as a prototype parasympatholytic
agent, 84
Parasympatholytic effects, 84
Sympathetic Branch, 84
Adrenergic neurotransmitter function, 85
Enzyme inactivation, 86
Sympathetic (adrenergic) receptor types, 86
Sympathomimetic and Sympatholytic Agents, 89
Neural Control of Lung Function, 89
Sympathetic innervation and effects, 90
Parasympathetic innervation and effects, 92
Nonadrenergic noncholinergic inhibitory
nerves, 94
Nonadrenergic noncholinergic excitatory
nerves, 95
UNIT TWO
DRUGS USED TO TREAT THE RESPIRATORY
SYSTEM
6 Adrenergic (Sympathomimetic)
Bronchodilators, 101
Introduction, 101
History and Development, 101
Agents and Clinical Use, 102
Indication for use, 102
Mode of Action, 102
Beta and aIpha 2 receptor activation, 103
Alpha 1 receptor activation, 103
Specific Adrenergic Agents, 105
Catecholamines, 105
Resorcinol agents, 108
Saligenin agents, 109
Pirbuterol, 109
A pro drug: bitolterol, 109
Ephedrine, 110
Long acting beta adrenergic agents, 111
Investigational long acting beta adrenergic
agents, 114
Drug Formulations, 115
Routes of Administration, 115
Inhalation route, 116
Oral route, 116
Parenteral administration, 117
Adverse Side Effects, 117
Tremor, 118
Cardiac effects, 118
Tachyphylaxis and tolerance, 119
Central nervous system effects, 121
Fall in Pao2, 121
Metabolic disturbances, 121
Propellant toxicity and paradoxical
bronchospasm, 121
Sulfite sensitivity, 122
The Beta Agonist Controversy, 122
Conclusions and Recommendations, 123
7 Anticholinergic (Parasympatholytic)
Bronchodilators, 127
Introduction, 127
History and Development, 127
Agents and Clinical Use, 128
Indications for use, 128
Mode of Action, 128
Vagally mediated reflex bronchoconstriction, 129
Muscarinic receptor subtypes, 129
Clinical Pharmacology, 132
Structure activity relations, 132
Pharmacokinetics of ipratropium, 132
Pharmacologic effects of anticholinergic
agents, 133
Specific Anticholinergic (Parasympatholytic)
Agents, 134
Clinical Application, 137
Use in COPD, 137
Use in asthma, 137
Combination therapy: beta adrenergic and
anticholinergic agents, 138
8 Xanthines, 142
Introduction, 142
Identification, 142
Xanthine derivatives, 142
General Pharmacologic Properties, 142
Clinical Uses, 143
Mode of Action, 143
Structure activity relations, 143
Theories of activity, 143
Conclusion, 145
I
Titrating Theophylline Doses, 145
Equivalent doses of theophylline salts, 145
Serum levels of theophylline, 146
Dosage schedules, 147
Theophylline Toxicity and Side Effects, 147
Factors Affecting Theophylline Activity, 148
Clinical Application, 149
Nonbronchodilating effects of theophylline, 149
Conclusion, 150
9 Mucus Controlling Drug Therapy, 153
Introduction, 153
Drug Control of Mucus: A Perspective, 153
Physiology of the Mucociliary System, 154
Source of airway secretions and terminology, 154
Surface epithelial cells, 155
Subepithelial cells, 156
Ciliary system, 156
Factors affecting mucociliary transport, 158
Milk intake and mucus production, 158
Nature of Mucus Secretion, 159
Structure and composition of mucus, 159
Epithelial ion transport and airway surface
fluid, 160
Mucus in disease states, 161
Physical Properties of Mucus, 162
Adhesive forces, 162
Cohesive forces, 162
Mucus as a viscoelastic material, 163
Spinability of mucus, 164
Non Newtonian nature of mucus, 164
Mucus Controlling Agents, 164
Mucolysis and mucociliary clearance, 164
Acetylcysteine (Mucomyst), 165
Indications for use, 165
Dose and administration, 165
Mode of action, 166
Hazards, 166
Incompatibility with antibiotics in mixture, 166
Use with acetaminophen overdose, 167
Antioxidant properties of acetylcysteine, 167
Dornase Alfa (Pulmozyme), 167
Indication and use in cystic fibrosis, 167
Mode of action, 168
Dose and administration, 169
Adverse effects, 169
Clinical application and evaluation, 169
Inhaled Amiloride, 169
Identification, 169
Clinical use, 169
Mode of action, 169
Aerosol administration, 170
Triphosphate Nucleotides (ATP, UTP), 170
Gelsolin, 170
Surface Active Phospholipids, 170
Contents xiii
Antiproteases, 171
Gene Therapy, 171
Other Mucoactive Agents, 171
Effect of Bland Aerosols on Mucus, 172
Future Mucus Controlling Agents, 172
10 Surfactant Agents, 177
Introduction, 177
Physical Principles of Surfactant Agents, 177
Application to the lung, 177
Previous Surfactant Agents in Respiratory Care, 178
Ethyl alcohol (ETOH), 178
Mucus wetting agents (detergents), 179
Use of phospholipids for mucus adhesiveness, 180
Exogenous Surfactants, 180
Introductory overview, 180
History and development of exogenous
surfactants, 180
Composition of pulmonary surfactant, 181
Production and regulation of surfactant
secretion, 182
Types of exogenous surfactant preparations, 183
Clinical Application of Exogenous Surfactants, 184
Clinical indications, 184
Clinical effect of exogenous surfactants, 184
Colfosceril palmitate (Exosurf), 185
Beractant (Survanta), 185
Hazards and complications of surfactant
therapy, 186
Factors in surfactant selection, 187
Future directions in surfactant therapy, 188
11 Corticosteroids in Respiratory Care, 191
Introduction, 191
Physiology of Corticosteroids, 191
Identification and source, 191
The hypothalamic pituitary adrenal axis, 192
HPA suppression with steroid use, 192
The diurnal steroid cycle, 193
Alternate day steroid therapy, 194
Nature of the Inflammatory Response, 194
Inflammation, 194
Inflammation in the airway, 194
Pharmacology of Corticosteroids, 196
Mode of action, 196
Effect on white cell count, 198
Effect on beta receptors, 198
Aerosolized Corticosteroids, 198
Early trials of aerosol steroids, 198
Topical to systemic activity ratios, 198
Aerosolized corticosteroid agents, 199
Intranasal corticosteroids, 201
Hazards and Side Effects of Steroids, 201
Systemic administration of steroids, 201
xiv Contests
Systemic side effects with aerosol
administration, 203
Topical (local) side effects with aerosol
administration, 204
Clinical Application of Aerosol Steroids, 205
Indications for use, 205
Use in asthma, 205
Use in chronic obstructive pulmonary disease, 206
Androgenic (Anabolic) Corticosteroids, 206
Use in sports, 207
12 Mediator Antagonists, 211
Introduction, 211
Mechanisms of Inflammation in Asthma, 211
The immunologic (allergic) response, 211
Cromolyn Sodium (Disodium Cromoglycate), 214
Indications for use, 215
Mode of action, 215
Dose and administration, 216
Side effects, 218
Clinical efficacy of cromolyn sodium, 218
Clinical application of cromolyn sodium, 218
Nedocromil Sodium (Tilade), 219
Indication for use, 219
Dose and administration, 219
Mode of action, 219
Side effects, 221
Clinical efficacy, 221
Zafirlukast (Accolate), 222
Mode of action, 222
Pharmacokinetics, 224
Side effects, 224
Clinical application, 224
Zileuton (Zyflo), 224
Mode of action, 224
Hazards and side effects, 225
Clinical efficacy, 225
Future Directions for Asthma Therapy, 225
13 Aerosolized Antiinfective Agents, 228
Introduction, 228
Aerosolized Pentamidine, 228
Indication for use, 229
Rationale for aerosol administration, 229
Description of PCP, 229
Mode of action of pentamidine, 230
Side effects, 230
Administration of aerosolized pentamidine, 231
Environmental exposure, 232
Environmental precautions, 233
Aerosol therapy for prophylaxis—clinical
application, 233
Aerosol therapy of acute PCP, 234
Ribavirin, 234
Indication for use, 234
Nature of viral infection, 235
Respiratory syncytial virus infection, 235
Mode of action of ribavirin, 235
Side effects, 238
Administration and dose, 238
Environmental contamination, 239
Clinical application of ribavirin, 239
Respiratory Syncytial Virus Immune Globulin
Intravenous (Human), 240
Indication for use, 240
Administration and dosage, 240
Adverse reactions, 240
Aerosolized Antibiotics, 240
General use of aerosol antibiotics, 240
Aerosol antibiotics in cystic fibrosis, 240
Aerosol administration, 241
Clinical efficacy of inhaled antibiotics, 242
Side effects, 242
Topical Antibiotics for Orophaiyngeal
Decontamination, 243
14 Antiinfective Agents, 247
Introduction, 247
Terms and Concepts, 247
Modes of action of antibiotics, 248
Terms describing antibiotic activity, 248
Sensitivity and resistance, 249
Resistance to antibiotics, 249
The Beta lactam Antibiotics, 250
Penicillins, 251
Mode of action, 251
Resistance, 252
Penicillin allergy, 252
Uses, 252
Cephalosporins, 252
Mode of action, 252
Toxicity and hazards, 252
Uses, 253
Carbapenems, 253
Monobactam, 253
Aminoglycosides, 253
Mode of action, 253
Uses, 253
Toxicity, 254
Tetracyclines, 254
Mode of action, 254
Toxicity and hazards, 254
Uses, 254
Fluoroquinolones, 254
Polymyxins, 255
Macrolide Antibiotics (Erythromycins), 255
j
• Sulfonamides, 255
Mode of action, 255
Uses, 256
Trimethoprim sulfamethoxazole (TMP SMX), 256
Miscellaneous Antibiotic Agents, 256
Vancomycin (Vancocin), 256
Chloramphenicol (Chloromycetin), 256
Lincosamides, 256
Bacitracin, 257
Metronidazole (Flagyl, Metizole), 257
Nitrofurantoin (Furadantin), 257
Antifungal Agents, 257
Amphotericin B, 257
Nystatin, 257
Griseofulvin, 258
Flucytosine (Ancobon), 258
Azole antifungal agents, 258
Antituberculosis Agents, 258
Six and nine month treatment regimens, 259
Streptomycin, 259
Isoniazid, 259
Rifampin, 260
Ethambutol, 260
Pyrazinamide, 260
Second line agents, 260
HIV and TB infection, 260
Drug resistant TB, 260
Antiviral Agents, 260
Modes of action, 261
Interferons, 262
15 Cold and Cough Agents, 265
Introduction, 265
Sympathomimetic (Adrenergic) Decongestants, 265
Topical application, 265
Systemic application, 266
Antihistamine Agents, 266
Effect of histamine, 266
Histamine receptors, 267
Antihistamine agents, 267
Effects of antihistamines, 268
Structure activity relations, 268
Use with colds, 268
Treatment of seasonal allergic rhinitis, 269
Expectorants, 270
Efficacy and use, 270
Use in chronic bronchitis, 270
Mode of action, 270
Expectorant agents, 270
Cough Suppressants (Antitussives), 271
Agents and mode of action, 272
Use of cough suppressants, 272
Cold Compounds, 272
Treating a cold, 273
COMTE TS XV
16 Selected Agents Used in Respiratory
Disease, 275
Introduction, 275
Alpha 1 proteinase Inhibitor (Human), 275
Alpha 1 antitrypsin deficiency, 275
Genetics, 276
Indication for drug therapy, 276
Administration and dose, 276
Hazards and side effects, 277
Nicotine Replacement Therapy, 277
Indications for use, 278
Drug formulations, 278
Precautions, 279
Nitric Oxide, 279
Indications for use, 279
Pharmacology of nitric oxide, 279
Effect on the pulmonary circulation, 280
Toxicity, 280
Administration, 281
17 Aerosolized Drug Delivery in Neonates
and Children, 283
Introduction, 283
Factors Affecting Drug Therapy in the Young, 283
Pharmaceutical factors, 283
Pharmacokinetic factors, 284
Pharmacodynamic factors, 284
Calculating Pediatric Doses, 284
Pediatric Doses of Aerosolized Drugs, 285
Pediatric Aerosol Administration, 285
Metered dose inhaler, 285
Dry powder inhalers, 285
Jet nebulizers, 287
Aerosol delivery with facemasks or endotracheal
tubes, 287
Conclusion, 287
UNIT THREE
CRITICAL CARE AMD CARDIOVASCULAR DRUG
CLASSES
18 Skeletal Muscle Relaxants (Neuromuscular
Blocking Agents), 293
Introduction, 293
History and Development, 293
Use of Neuromuscular Blocking Agents, 294
Physiology of the Neuromuscular Junction, 294
Nondepolarizing Agents, 295
Mode of action, 295
Pharmacokinetics of nondepolarizing
agents, 296
Adverse effects and hazards, 297
Reversal of nondepolarizing blockade, 297
xvi Contents
Depolarizing Agents, 298
Mode of action, 298
Reversal, 299
Use of hexafluorenium, 299
Adverse effects and hazards, 299
Sensitivity to succinylcholine, 299
Desensitization (Phase II) block, 300
Use with Ventilator Patients, 300
Precautions and risks, 300
Choice of agents, 300
Interaction with antibiotics, 301
Use of sedatives and analgesics, 301
Monitoring, 302
19 Cardiac Drugs, 305
Introduction, 305
The Cardiovascular System, 305
Factors affecting blood pressure, 305
The Heart, 306
Action potentials, 307
Basic arrhythmias, 308
Terminology of cardiac and cardiovascular
agents, 308
Central venous and pulmonary artery wedge
pressure, 309
Cardiotonic (Positive Inotropic) Drugs, 310
Cardiac glycosides, 310
Phosphodiesterase inhibitors, 310
Beta adrenergic cardiac stimulants, 310
Antiarrhythmic Agents, 311
Class I antiarrhythmic agents, 312
Class II antiarrhythmic agents, 313
Class III antiarrhythmic agents, 314
Class IV antiarrhythmic agents, 315
Other antiarrhythmic agents, 315
Drugs Used in Advanced Cardiac Life
Support, 316
20 Drugs Affecting Circulation, 319
Introduction, 319
The Circulatory System, 319
Hypertension and Treatment, 319
Antihypertensive Drug Classes, 321
Diuretics, 321
Centrally acting antiadrenergic agents, 321
Peripherally acting antiadrenergic agents, 322
Beta adrenergic blockade, 322
Alpha and beta adrenergic blockade, 323
Vasodilators, 323
Angiotensin converting enzyme
inhibition, 323
Angiotensin II antagonists, 323
Acute antihypertensive agents, 323
Miscellaneous agents, 324
Antianginal Agents, 324
The nitrates and nitrites, 324
Calcium channel blocking agents, 325
Beta adrenergic blocking agents, 325
Vasoconstricting Agents (Vasopressors), 325
Hemodynamic effects, 326
Antithrombotic Drug Classes, 327
Blood coagulation and thrombus
formation, 327
Anticoagulant agents, 327
Antiplatelet agents, 330
Thrombolytic agents, 330
21 Diuretic Agents, 333
Introduction, 333
Renal Structure and Function, 333
Nephron function, 333
Electrolyte filtration and reabsorption, 334
Acid base balance, 334
Diuretic Groups, 335
Osmotic diuretics, 336
Carbonic anhydrase inhibitors, 337
Thiazide diuretics, 337
Loop diuretics, 337
Potassium sparing diuretics, 338
Other diuretic groups, 338
22 Drugs Affecting the Central Nervous
System, 341
Introduction, 341
The Central Nervous System, 341
The cortex, 342
Themidbrain, 342
The medulla, 342
The reticular activating system, 342
The limbic system, 343
The extrapyramidal system, 342
CNS drugs and sleep states, 343
Sedatives and Hypnotics, 344
Barbiturates, 344
Clinical pharmacology, 344
Mechanism of action, 345
Clinical effects, 346
Barbiturate intoxication, 347
Nonbarbiturate Sedatives and Hypnotics, 347
Benzodiazepine hypnotics, 347
Ethyl alcohol, 348
General Anesthetics, 348
The barbiturate anesthetics, 349
Nonbarbiturate anesthetics, 349
Anesthetic gases, 349
Local Anesthetics, 350
Mechanism of action, 350
Types of agents, 350
Psychotherapeutic Agents, 351
The minor tranquilizers, 351
Antipsychotic drugs (neuroleptics), 352
Antidepressants, 353
Analgesics, 354
Narcotic (opioid) analgesics, 354
Pharmacologic properties of morphine, 355
Therapeutic uses of narcotics, 355
Overdose of morphine and its derivatives, 356
Narcotic antagonists, 357
Nonnarcotic analgesics, 357
Respiratory Stimulants, 358
Agents, 359
Clinical use, 359
Contents xvii
APPENDIX A
Answers to assessment questions and clinical
scenarios, 363
APPENDIX B
Units and systems of measurement, 382
APPENDIX C
Recommendations on use of aerosol generators, 384
APPENDIX D
Pharmacologic management of asthma and COPD, 387
APPENDIX E
Drug induced pulmonary disease, 390
GLOSSARY OF SELECTED TERMS, 391
|
| any_adam_object | 1 |
| author | Rau, Joseph L. |
| author_facet | Rau, Joseph L. |
| author_role | aut |
| author_sort | Rau, Joseph L. |
| author_variant | j l r jl jlr |
| building | Verbundindex |
| bvnumber | BV011994191 |
| callnumber-first | R - Medicine |
| callnumber-label | RM388 |
| callnumber-raw | RM388 |
| callnumber-search | RM388 |
| callnumber-sort | RM 3388 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XI 4200 |
| ctrlnum | (OCoLC)37213998 (DE-599)BVBBV011994191 |
| dewey-full | 616.2/00461 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.2/00461 |
| dewey-search | 616.2/00461 |
| dewey-sort | 3616.2 3461 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 5. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01550nam a2200433 c 4500</leader><controlfield tag="001">BV011994191</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19980909 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">980609s1998 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">081512337X</subfield><subfield code="9">0-8151-2337-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)37213998</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011994191</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM388</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.2/00461</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4200</subfield><subfield code="0">(DE-625)153004:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rau, Joseph L.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Respiratory care pharmacology</subfield><subfield code="c">Joseph L. Rau</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">5. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">St. Louis [u.a.]</subfield><subfield code="b">Mosby</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVII, 408 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bronchodilator Agents</subfield><subfield code="x">administration & dosage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bronchodilator Agents</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Atemwege</subfield><subfield code="0">(DE-588)4068903-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Atemwege</subfield><subfield code="0">(DE-588)4068903-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008117173&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008117173</subfield></datafield></record></collection> |
| id | DE-604.BV011994191 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:19:52Z |
| institution | BVB |
| isbn | 081512337X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008117173 |
| oclc_num | 37213998 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | XVII, 408 S. Ill., graph. Darst. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Mosby |
| record_format | marc |
| spelling | Rau, Joseph L. Verfasser aut Respiratory care pharmacology Joseph L. Rau 5. ed. St. Louis [u.a.] Mosby 1998 XVII, 408 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Bronchodilator Agents administration & dosage Bronchodilator Agents pharmacology Respiratory Therapy Respiratory agents Respiratory therapy Atemwege (DE-588)4068903-7 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Atemwege (DE-588)4068903-7 s Pharmakotherapie (DE-588)4076066-2 s DE-604 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008117173&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Rau, Joseph L. Respiratory care pharmacology Bronchodilator Agents administration & dosage Bronchodilator Agents pharmacology Respiratory Therapy Respiratory agents Respiratory therapy Atemwege (DE-588)4068903-7 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| subject_GND | (DE-588)4068903-7 (DE-588)4076066-2 |
| title | Respiratory care pharmacology |
| title_auth | Respiratory care pharmacology |
| title_exact_search | Respiratory care pharmacology |
| title_full | Respiratory care pharmacology Joseph L. Rau |
| title_fullStr | Respiratory care pharmacology Joseph L. Rau |
| title_full_unstemmed | Respiratory care pharmacology Joseph L. Rau |
| title_short | Respiratory care pharmacology |
| title_sort | respiratory care pharmacology |
| topic | Bronchodilator Agents administration & dosage Bronchodilator Agents pharmacology Respiratory Therapy Respiratory agents Respiratory therapy Atemwege (DE-588)4068903-7 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| topic_facet | Bronchodilator Agents administration & dosage Bronchodilator Agents pharmacology Respiratory Therapy Respiratory agents Respiratory therapy Atemwege Pharmakotherapie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008117173&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT raujosephl respiratorycarepharmacology |